ArticleAmerican journal of cancer research2026
PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring PIM1 Kinase as a Therapeutic Target: Mechanisms and Strategies in Cancer Treatment.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is among the top ten most common cancers diagnosed in the United States. The incidence of RCC has continued to increase in recent years, yet our understanding of its etiology is incomplete. Clear cell RCC (ccRCC) is the major subtype, constituting over 75% of all RCC cases. Treatment options for RCC are limited in efficacy, as RCC tumors typically acquire resistance to current therapies, particularly in advanced and metastatic RCC. von Hippel-Lindeau (VHL) status is the only clinically validated biomarker approved for therapeutic intervention in RCC to date. The identification of novel molecular targets is therefore critical for improving therapeutic strategies for RCC. PIM1 is a constitutively active serine/threonine kinase involved in promoting proliferation, invasion, migration, and apoptosis evasion in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.